Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade

Japanese Journal of Clinical Oncology

Volumn 38, Issue 9, 2008, Pages 617-622

  Soga, Norihito ^a   Arima, Kiminobu ^a   Sugimura, Yoshiki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Delayed CAB; Nadir PSA; PSA biochemical failure

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREDICTION; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK FACTOR; BLOOD; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG MONITORING; MIDDLE AGED; PROSTATE TUMOR; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUPROLIDE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITRILES; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TOSYL COMPOUNDS; TREATMENT FAILURE;

EID: 52449108056     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn071     Document Type: Article

References (22)

1. Fall KGH, Andren O, Bill-Axelson A, Adolfsson J, Adami HO, et al. Scandinavian Prostate Cancer Group Study No. 4. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99:526-32.
2. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134-41.
3. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci 2006;97:243-7.
4. Vikram B. Re: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1826.
5. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002;95:361-76.
6. Moul JW, Fowler JE, Jr. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. Urology 2003;62:20-8.
7. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004;93:1177-82.
8. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2007;25:1596-605.
9. Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, et al. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int 2005;96:503-7.
10. Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 2004;63:732-6.
11. Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, et al. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int 2006;97:1184-9.
12. Soga N, Onishi T, Arima K, Sugimura Y. PSA half-life and pretreatment PSA: The crucial predictors for PSA trend in delayed-CAB therapy. INT J Urol 2007;14:192-6.
13. Fowler JE, Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995;154:448-53.
14. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000;163:1743-6.
15. van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, Schimmel EC, Huizenga H, van Daal WA, et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol 2006;24:4581-6.
16. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001;166:1322-7.
17. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-90.
18. D'Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/ml. Int J Radiat Oncol Biol Phys 1997;37:1053-8.
19. Kakinuma H, Sasaki R, Sato K, Hirano S, Miura K, Sasaki S, et al. Prognostic importance of prostate specific antigen in patients with hormonally treated stage D2 prostate carcinoma. Nippon Hinyokika Gakkai Zasshi 1996;87:997-1003.
20. Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: Results of a 10-year follow-up. BJU Int 2006;98: 573-9.
21. Namiki M, Ueno S, Kitagawa Y, Konaka H, Mizokami A, Koh E, et al. Hormonal therapy. Int J Clin Oncol 2007;12:427-32.
22. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: What do we really know? Nat Clin Pract Urol 2008;5:24-34.